Citation Impact
Citing Papers
Reassessing Epithelial to Mesenchymal Transition as a Prerequisite for Carcinoma Invasion and Metastasis
2006
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Pharmacokinetics of the nonsteroidal steroid sulphatase inhibitor 667 COUMATE and its sequestration into red blood cells in rats
2004
Mechanisms of Endocrine Resistance in Breast Cancer
2010
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Computation and Functional Studies Provide a Model for the Structure of the Zinc Transporter hZIP4
2015 StandoutNobel
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
2005
Hallmarks of Cancer: The Next Generation
2011 Standout
Modulation of Epidermal Growth Factor Receptor in Endocrine‐Resistant, Estrogen‐Receptor‐Positive Breast Cancer
2002
The relationship between prognostic and predictive factors in the management of breast cancer
1998
E-cadherin as a prognostic indicator in primary breast cancer
2001
Prognostic Factors in Breast Cancer
2000
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
2011 Standout
P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast
2002
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
2014 StandoutNobel
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Overview of mammalian zinc transporters
2004
Control of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase
2009 StandoutNobel
Breast cancer
2016 Standout
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene
2003 StandoutNobel
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Molecular mechanisms of epithelial–mesenchymal transition
2014 Standout
CDK-Independent Activation of Estrogen Receptor by Cyclin D1
1997
Epithelial-Mesenchymal Transitions
2004 Standout
Stat3 as an Oncogene
1999 Standout
Introduction of Fluorine and Fluorine‐Containing Functional Groups
2013 Standout
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
2010
Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance
2010
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
2012 StandoutNature
Induction of Germline Transcription in the TCRγ Locus by Stat5
1999 StandoutNobel
Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer
2003
Role of the retinoblastoma protein in the pathogenesis of human cancer.
1997 StandoutNobel
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase
2002 Standout
Clinical potential of new antiestrogens.
1997
Historical perspective on hormonal therapy of advanced breast cancer
2002
Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer
2004 Nature
Pathological prognostic factors in breast cancer
1999 Standout
Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype
2006
A Good Drug Made Better: The Fulvestrant Dose-Response Story
2014
Levels of Hypoxia-Inducible Factor-1 During Breast Carcinogenesis
2001 StandoutNobel
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer
2006
Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells
1996
Secretory meningioma
1997
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
The SLC39 family of metal ion transporters
2004
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
2005 Standout
The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen
1998 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Similarities and distinctions in the mode of action of different classes of antioestrogens.
2000
Pancreatic Cancer
2010 Standout
Future directions of bone-targeted therapy for metastatic breast cancer
2010
‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)
2004
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
2004
Adjuvant therapies for special types of breast cancer
2011
Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy
1996
Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials
2004
Sulfur(VI) Fluoride Exchange (SuFEx): Another Good Reaction for Click Chemistry
2014 StandoutNobel
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Endocrine treatment options for advanced breast cancer – the role of fulvestrant
2004
First international consensus guidelines for breast cancer in young women (BCY1)
2014
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine
2008
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy
2007
Brain Tumors
2001 Standout
Chemotherapy: induction of stress responses
2006
Sulfatase-activated fluorophores for rapid discrimination of mycobacterial species and strains
2013 StandoutNobel
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)*
2001
Fluorine in medicinal chemistry
2007 Standout
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
The natural history of breast carcinoma
1999
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
2000
Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments
2000
The Snail genes as inducers of cell movement and survival: implications in development and cancer
2005
Fulvestrant (Faslodex®)—How to Make a Good Drug Better
2007
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
A potent specific pure antiestrogen with clinical potential.
1991 Standout
Breast cancer and hormone-replacement therapy in the Million Women Study
2003 Standout
The NEDD8 Pathway Is Required for Proteasome-Mediated Degradation of Human Estrogen Receptor (ER)-α and Essential for the Antiproliferative Activity of ICI 182,780 in ERα-Positive Breast Cancer Cells
2003
Identification and Characterization of a Constitutively Active STAT5 Mutant That Promotes Cell Proliferation
1998
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study
1998 StandoutScience
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance
2004
Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor α (ERα), Differentially Affect ERα Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells
2003
Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A
1986 StandoutNature
Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies
2010
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
The natural history of breast carcinoma: what have we learned from screening?
1999
Crosstalk between Estrogen Receptor and Growth Factor Receptor Pathways as a Cause for Endocrine Therapy Resistance in Breast Cancer
2005
beta1 integrin as a molecular therapeutic target
2007
A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer
2011
Estrogen and progesterone receptor proteins in breast cancer
1979
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
The association of cytosol oestrogen and progesterone receptors with histological features of breast cancer and early recurrence of disease
1983
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older.
2002
LIV-1 enhances the aggressive phenotype through the induction of epithelial to mesenchymal transition in human pancreatic carcinoma cells
2009
Fluorine in medicinal chemistry: A review of anti-cancer agents
2006
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
2008
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Sulfamic Acid and Its N- and O-Substituted Derivatives
2013
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
Autophagy as a Regulated Pathway of Cellular Degradation
2000 StandoutScience
Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition
2005
A New Portal to SuFEx Click Chemistry: A Stable Fluorosulfuryl Imidazolium Salt Emerging as an “F−SO2+” Donor of Unprecedented Reactivity, Selectivity, and Scope
2017 StandoutNobel
Metals in Neurobiology: Probing Their Chemistry and Biology with Molecular Imaging
2008 Standout
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
2006 StandoutScience
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
Structures of Human Carbonic Anhydrase II/Inhibitor Complexes Reveal a Second Binding Site for Steroidal and Nonsteroidal Inhibitors,
2010
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
1998
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of R.I. Nicholson being referenced
An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast.
1991
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer
2005
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.
2001
Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer
2006
A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification
1991
Oestrogen-regulated genes in breast cancer: Association of pLIV1 with lymph node involvement
1994
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells
2008
Non-steroidal and steroidal sulfamates: new drugs for cancer therapy
2001
Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast
1993
Actions of oestrogens and antioestrogens on rat mammary gland development: Relevance to breast cancer prevention
1988
Comparison of the Effects of a Pure Steroidal antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer
1995
Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer
2005
Estrogen Deprivation in Breast Cancer
1990
Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy
2004
Clinical Value of Epidermal Growth Factor Receptor Expression in Primary Breast Cancer
2005
Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells
2006
erbB signalling in clinical breast cancer: relationship to endocrine sensitivity
1997
EARLY INCREASES IN RIBONUCLEIC ACID POLYMERASE ACTIVITIES OF DIMETHYLBENZANTHRACENE-INDUCED MAMMARY TUMOUR NUCLEI IN RESPONSE TO OESTRADIOL-17β AND TAMOXIFEN
1977
HISTOLOGICAL GRADE AND RESPONSE TO ENDOCRINE THERAPY IN BREAST CANCER
1981
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.
1994
The significance of p53 autoantibodies in the serum of patients with breast cancer.
1996
An immunohistochemical examination of the expression of E-cadherin, ?- and ?/?-catenins, and ?2- and ?1-integrins in invasive breast cancer
1999
Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated with MIBI antibody
1997